Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Discovery

Novartis partners with Dunad for protein degrader therapies

by Ryan Cross
November 7, 2021 | A version of this story appeared in Volume 99, Issue 41

 

Novartis is expanding its investment in protein degradation therapies through a partnership with the British start-up Dunad Therapeutics. Novartis will pay Dunad $24 million up front and provide research funding to develop small-molecule drug candidates for up to four protein targets. Novartis has the exclusive option to license and clinically test the compounds, and Dunad could earn up to $1.3 billion in milestone payments. The investment bolsters Novartis’s own cancer-focused protein degradation projects.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.